Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

Phase 2 Not yet recruiting 90 enrolled OHSU Knight Cancer Institute National Heart, Lung, and Blood Institute (NHLBI) · collab Oregon Health and Science University · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.

Timeline

Start: 2026-02-28
Primary completion: 2029-02-02
Completion: 2029-10-02

Publications

Background Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4. doi: 10.1111/j.1538-7836.2005.01204.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gruticibart	Protein / enzyme biologic	2 mg/kg	Intravenous

Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

Summary

Timeline

Publications

Drugs

Indications